E7016
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for E7016, covering 2016-07-28 to 2024-10-10. Get the full timeline:
Most recent: Clinical Trial Update: Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors [Phase 1]